Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

VOLUNTARY ANNOUNCEMENT - SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

June 10, 2025

VOLUNTARY ANNOUNCEMENT - SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Previous: VOLUNTARY ANNOUNCEMENT - ENTERING INTO STRATEGIC RESEARCH COLLABORATION AGREEMENT WITH ASTRAZENECA

Next: VOLUNTARY ANNOUNCEMENT - COBAMAMIDE CAPSULES OBTAIN DRUG REGISTRATION APPROVAL

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat